PRODUCT DESCRIPTION
Synvisc It is composed of Hylan G-F 20 is a sterile viscoelastic liquid, apoish, containing Hylan.Hylan G-F 20 temporarily reconstitutes the viscoelasticity of the synovial liquid, brings clinical benefits to patients in all stages of arthrosis of the joints, is more effective in patients who actively and regularly use the articulation affected by the pathology, and reaches its therapeutic effect through theViscosupplementation, a process through which the physiological state and the retiological characteristics of the synovial fluid of the arthritic articulation are reintegrated.Hylan are derived from hyaluronate (sodium salt of hyaluronic acid) and are made up of unconventional unconventive units of n-acetylglucosamine and sodium glucuronate.Hylan A has an average molecular weight of about 6,000,000 Dalton and Hylan B is an hydrogel.Hylan G-F 20 contains Hylan A and B (8.0 mg ± 2.0 mg per ml) in sodium chloride buffered physiological solution (pH 7.2 ± 0.3).
Viscosupplement with Hylan G-F 20 is indicated to relieve pain and functional limitations, allowing a more extensive movement of the joint.In vitro studies have shown that Hylan G-F 20 protects cartilage cells from damage due to the action of physical and chemical agents.
Synvisc-One is indicated only for the intra-articular use by a doctor in the treatment of pain associated with knee arthrosis.
Dosage
The dosage scheme of Hylan G-F 20 depends on the joint to be treated.
Knee arthrosis: recommended treatment regime for Synvisc is three injections of 2 ml in the knee, after a week from each other.To achieve the optimal effect, it is essential to practice all three injections.The recommended maximum dosage is six injections over six months, with a pause of at least four weeks between the treatment regimes.
Artosis of the hip, ankle and shoulder: recommended initial treatment regime is a single injection of 2 ml.However, it is recommended to practice a second injection of 2 ml if an adequate symptomatic benefit of pain is not obtained.Clinical data have shown that patients benefit from this second injection if practiced after one-three months from the first
Generally a maximum duration of the effect has been found for patients who respond well to treatment up to 26 weeks, even if shorter or longer periods have been observed.Data extrapolated from perspective clinical studies conducted on patients with knee arthrosis have shown treatment benefits of up to 52 weeks, after a single treatment cycle of three synvisc injections.
Ingredients/INCI
Each ml contains: Hylan 8.0 mg, sodium chloride 8.5 mg, disodium phosphate hydrogen 0.16 mg, dioxide sodium phosphate hydrated 0.04 mg, water for preparations injectable enough.
Format
Package with 3 glass syringes of 2.25 ml caduna pre -rated with 2 ml caduna.of Hylan G-F 200. Store at a temperature between +2 ° C and +30 ° C.Do not freeze.
